Schwartz, H I <br/><br/>
Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori.  [electronic resource] 

 -  Helicobacter  Jun 1999 
 - 121-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1083-4389 
<br/><br/><label>Standard No.: </label>10.1046/j.1523-5378.1999.98005.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Bacterial Agents--therapeutic use<br/>Anti-Ulcer Agents--therapeutic use<br/>Bismuth--adverse effects<br/>Clarithromycin--adverse effects<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Helicobacter Infections--drug therapy<br/>Helicobacter pylori--drug effects<br/>Humans<br/>Male<br/>Microbial Sensitivity Tests<br/>Middle Aged<br/>Ranitidine--adverse effects